Eisai

News

Eisai's brain health tool NouKNOW used in Tokyo dementia pro...

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia.

News

ASCO22: New data backs BMS' investment in Eisai's first canc...

Eisai's first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal from Bristol-Myers Squibb, and new data reported at ASCO has g

News

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another...

Here we go again.

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

News

Pharma group seeks digital measure standards for Alzheimer's

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the develo

News

Eisai hands off responsibility for Aduhelm to Biogen

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

Eisai's brain health tool NouKNOW used in Tokyo dementia pro...

ASCO22: New data backs BMS' investment in Eisai's first canc...

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another...

Idorsia is first to EU market with orexin insomnia drug

Pharma group seeks digital measure standards for Alzheimer's

Eisai hands off responsibility for Aduhelm to Biogen

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Eisai

Editor's Picks